Display options
Cite
Chima RS, Hake PW, Piraino G, et al. Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock. Int J Clin Exp Med. 2010;3(1):1-9
Chima, R. S., Hake, P. W., Piraino, G., Mangeshkar, P., O'Connor, M., & Zingarelli, B. (2010). Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock. International journal of clinical and experimental medicine, 3(1), 1-9.
Chima, Ranjit S, et al. "Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock." International journal of clinical and experimental medicine vol. 3,1 (2010): 1-9.
Chima RS, Hake PW, Piraino G, Mangeshkar P, O'Connor M, Zingarelli B. Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock. Int J Clin Exp Med. 2010 Jan 01;3(1):1-9. PMID: 20369035; PMCID: PMC2848301.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2010 Jan 01;3(1):1-9.

Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock.

International journal of clinical and experimental medicine

Ranjit S Chima, Paul W Hake, Giovanna Piraino, Prajakta Mangeshkar, Michael O'Connor, Basilia Zingarelli

Affiliations

  1. Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine Cincinnati, OH, USA.

PMID: 20369035 PMCID: PMC2848301

Abstract

Apoptosis or programmed cell death has been demonstrated to play a role in the development of lung injury following hemorrhagic shock. A major pathway modulating the apoptotic response is the phosphatidylinositol 3-kinase/serine/threonine kinase (PI3K/Akt) pathway. Ciglitazone, a peroxisome proliferator-activated receptor-y (PPARy) ligand has previously been shown to attenuate lung inflammation following hemorrhagic shock. In vivo similar ligands have demonstrated anti-apoptotic effects with a reduction in organ injury in models of acute illness. In this study we examined the effect of ciglitazone on apoptosis and PI3K/Akt signaling in the lung following severe hemorrhage and resuscitation. Hemorrhagic shock was induced in male Wistar rats by withdrawing blood from the femoral artery to a mean arterial pressure of 50 mmHg. Animals were kept in shock for 3h at which time they were rapidly resuscitated by returning their shed blood. At the time of resuscitation and every hour thereafter, groups of animals received ciglitazone (10mg/kg) or DMSO intraperitoneally. Vehicle-treated rats had increased lung apoptosis following hemorrhage and resuscitation by Tunel staining. This was associated with increased activity of caspase-3. Ciglitazone treatment reduced lung apoptosis with a significant reduction in caspase-3 activity. This was associated with increased phosphorylation of the pro-survival kinase Akt. Thus, our data suggest that ciglitazone, a PPARy ligand, promotes cell survival in the lung following hemorrhagic shock.

Keywords: Hemorrhagic shock; apoptosis; ciglitazone; lung injury; peroxisome proliferator-activated receptor-y; phospho-Akt

References

  1. Am Surg. 2004 Dec;70(12):1094-8 - PubMed
  2. Cardiovasc Res. 2009 Feb 1;81(2):344-52 - PubMed
  3. Science. 2002 May 31;296(5573):1655-7 - PubMed
  4. Surgery. 2005 Oct;138(4):749-57; discussion 757-8 - PubMed
  5. J Clin Endocrinol Metab. 2005 Dec;90(12):6678-86 - PubMed
  6. Nature. 1999 Sep 2;401(6748):33-4 - PubMed
  7. Crit Care Med. 2003 Apr;31(4 Suppl):S184-8 - PubMed
  8. J Cell Physiol. 2009 Jul;220(1):58-71 - PubMed
  9. J Trauma. 2002 Jan;52(1):104-11 - PubMed
  10. J Trauma. 2003 Oct;55(4):608-16 - PubMed
  11. Circulation. 2000 Mar 14;101(10):1165-71 - PubMed
  12. Am J Physiol Lung Cell Mol Physiol. 2009 Mar;296(3):L404-17 - PubMed
  13. Oncogene. 2003 Jul 3;22(27):4186-93 - PubMed
  14. Eur J Pharmacol. 1997 Oct 29;338(1):55-65 - PubMed
  15. Am J Pathol. 2002 Nov;161(5):1783-96 - PubMed
  16. J Biol Chem. 2007 Dec 21;282(51):37006-15 - PubMed
  17. J Am Coll Surg. 2001 Sep;193(3):255-63 - PubMed
  18. Crit Care Med. 2007 Sep;35(9 Suppl):S488-95 - PubMed
  19. Nat Rev Mol Cell Biol. 2004 Nov;5(11):897-907 - PubMed
  20. J Cell Biol. 1992 Nov;119(3):493-501 - PubMed
  21. J Immunol. 1999 Aug 15;163(4):2217-25 - PubMed
  22. Circulation. 2009 Mar 3;119(8):1124-34 - PubMed
  23. Am J Respir Crit Care Med. 2007 Sep 15;176(6):591-601 - PubMed
  24. Mol Cancer Res. 2007 Jun;5(6):523-30 - PubMed
  25. N Engl J Med. 2000 May 4;342(18):1334-49 - PubMed
  26. Am J Pathol. 2005 Dec;167(6):1545-59 - PubMed
  27. J Clin Invest. 2005 Oct;115(10):2618-24 - PubMed
  28. J Immunol. 2003 Dec 15;171(12):6827-37 - PubMed
  29. Crit Care Med. 2008 Oct;36(10):2849-57 - PubMed
  30. Shock. 2007 Nov;28(5):554-63 - PubMed
  31. Shock. 2006 May;25(5):432-9 - PubMed
  32. J Trauma. 2006 Jan;60(1):52-63 - PubMed
  33. Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L328-35 - PubMed
  34. Mol Med. 2008 Jul-Aug;14(7-8):465-75 - PubMed

Publication Types

Grant support